Rationale for a phase III clinical trial with AE-941 (Neovastat (R)) in metastatic renal cell carcinoma patients refractory to immunotherapy.B Escudier, F Patenaude,R Bukowski,P Champagne,P Falardeau,E DupontANNALS OF ONCOLOGY(2000)引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要